Jazz Pharmaceuticals Plc Stock News

MonotaRO, the Japanese business-to-business (B2B) e-commerce platform, was the largest detractor during the quarter. Pawn shop operator FirstCash was the top contributor during the quarter. Aggregates producer Martin Marietta Materials was a top contributor for the period.

Dr. Love, a biopharmaceutical industry veteran, brings extensive executive leadership and board experience with proven success in creating shareholder value DUBLIN , Oct. 28, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Ted W. Love, M.D.

DUBLIN , Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced it has entered into a research collaboration and drug supply agreement with Jazz Pharmaceuticals. Under the agreement, Jazz will provide zanidatamab (Ziihera®), a HER2-targeted bispecific antibody, at n...

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase 3 IMforte trial Zepzelca and atezolizumab combination added to National Comprehensive Cancer Network® Guidelines for SCLC For U.S. media and investors only DUBLIN , Oct. 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administr...

The U.S. Food and Drug Administration on Thursday has expanded the approval for Jazz Pharmaceuticals' therapy as a maintenance treatment of adult patients with a type of lung cancer.

Jazz Pharmaceuticals (JAZZ) receives a BUY rating, driven by strong DUET trial results for Xywav in narcolepsy and idiopathic hypersomnia. JAZZ's growth is anchored by Xywav and Epidiolex, both generating robust sales and supporting future oncology pipeline expansion. Recent clinical milestones, upcoming FDA decisions, and a well-executed leadership transition position JAZZ for long-term value ...

20 abstracts presented across World Sleep and Psych Congresses showcase Jazz's leadership in sleep medicine Novel results from the Phase 4 DUET trial underscore the significance of appropriate treatment options in adults with narcolepsy or idiopathic hypersomnia For U.S. media and investors only DUBLIN , Sept. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new ...